BoYen Therapeutics Inc. was established in June 2010. In its early years BoYen Therapeutics focused on new drug research and discovery, through our own proprietary prodrug technology platform, we perform chemosynthesis modification and create new patentable drug candidates. Our goal is to provide innovative medical options for patients, and maximize shareholder value at the same time.
After 10 years of painstaking work, we successfully created a prodrug technology platform which is capable of creating high-commercial-value patentable new drug candidates. Currently, BoYen Therapeutics also has a product pipeline with abundance of commercial value. BY-101 is an USFDA designated orphan drug with 7-year period marketing exclusivity. BY-101 is intended for the treatment of acute myeloid leukemia (AML). BY-102, BY-103 and BYT-3156 are patented drug candidates for the treatment of multiple sclerosis, leukemia, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and other indications.
The year 2020 is a year of transition for BoYen Therapeutics. The company decided it is time to commercialize its drug candidates and place most of its efforts on clinical development while maintaining a certain level of drug discovery to gradually increase its pipeline. BY-101 will enter Phase 2/3 clinical trials through USFDA 505(b)2 pathway in 2021. The company is also working on pre-clinical studies for BY-102, a drug candidate with an immense trillion-US dollar business opportunity.
The company also takes the initiative to explore collaboration with academic/research institutions to assist them in bringing their research work into drug development process, to create greater value and fruitful results for their hard work.
BoYen Therapeutics office is located in Taipei World Trade Center International Trade Building. In 2015, the company was approved and designated by the Industrial Development Bureau, Ministry of Economic Affairs as a Biotechnology New Drug Company.
